Precision BioSciences is claiming a major breakthrough in the race to cure Hepatitis B.
According to new clinical data released by Precision BioSciences at the EASL Congress today, their gene-editing therapy, PBGENE-HBV, successfully eliminated the virus’s “cccDNA” in liver biopsies. This is the first time a therapeutic agent has provided clinical evidence of directly inactivating the root cause of chronic Hepatitis B infection. The study data, presented by Dr. …